BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk ...
TCX-101 Clinical Program: TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse First patient to be enrolled in 4Q2024 Nomination of …